Brainstorm Cell Therapeutics Inc BCLI:NASDAQ

Earnings Announcement Next Earnings date is expected on 08/18/2022
Last Price$3.50NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$3.01 (1)
Ask (Size)$3.77 (8)
Day Low / HighN/A - N/A
Volume367.9 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Brainstorm Cell Therapeutics Inc ( NASDAQ )

Price: $3.50
Change: +0.55 (18.64%)
Volume: 367.9 K
3:59PM ET 8/12/2022
 
 

Champions Oncology Inc ( NASDAQ )

Price: $9.47
Change: +0.07 (0.74%)
Volume: 1.3 K
3:59PM ET 8/12/2022
 
 

Enzo Biochem Inc ( NYSE )

Price: $2.67
Change: -0.02 (0.74%)
Volume: 19.1 K
7:00PM ET 8/12/2022
 
 

Anixa Biosciences Inc ( NASDAQ )

Price: $4.06
Change: +0.16 (4.10%)
Volume: 67.6 K
3:59PM ET 8/12/2022
 
 

Galectin Therapeutics Inc ( NASDAQ )

Price: $2.07
Change: +0.04 (1.97%)
Volume: 57.0 K
4:00PM ET 8/12/2022
 

Read more news Recent News

Brainstorm Cell Therapeutics Gets New Brazilian Patent for NurOwn Technology
8:53AM ET 2/15/2022 MT Newswires

Brainstorm Cell Therapeutics (BCLI) said Tuesday the Brazilian Patent Office has granted it a new patent related to a method of manufacturing its NurOwn...

Brainstorm Cell Therapeutics Receives FDA Approval for NurOwn Dosing Extension; Shares Rise Pre-Bell
7:36AM ET 12/27/2021 MT Newswires

Brainstorm Cell Therapeutics (BCLI) said it plans to extend dosing of NurOwn for participants who completed the expanded access protocol, and that the US...

Brainstorm Cell Therapeutics Chief Financial Officer Preetam Shah Plans to Resign at August End
5:24PM ET 8/25/2021 MT Newswires

Brainstorm Cell Therapeutics (BCLI) said late Wednesday Chief Financial Officer Preetam Shah has notified the company of his intention to resign, effective...

Company Profile

Business DescriptionBrainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ. View company web site for more details
Address1325 Avenue of Americas
New York, New York 10019
Phone+1.201.488.0460
Number of Employees31
Recent SEC Filing05/16/202210-Q
Chief Executive OfficerChaim Lebovits
President & Chief Medical OfficerRalph Z. Kern
Chief Operating Officer & Executive Vice PresidentDavid Setboun
Chief Financial Officer & ControllerAlla Patlis

Company Highlights

Price Open$2.96
Previous Close$2.95
52 Week Range$2.52 - 4.46
Market Capitalization$127.7 M
Shares Outstanding36.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/18/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.64
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-104.15%

Analyst Ratings as of 05/24/2022

Buy
1
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset